{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-028759","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.354907+00:00","generated_at":"2026-06-22T03:12:02.965476+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ocugen Q3 net loss $0.10/share, cash $101.6M; advances OCU400 gene therapy and adds OCU500 mucosal vaccine","bullets":["Net loss per share $0.10 vs $0.05 YoY; R&D $15.6M (up from $6.3M).","Cash and equivalents $101.6M at Sep 30, 2022; provides runway into Q4 2023.","COVAXIN Phase 2/3 enrollment completed; top-line data expected early 2023.","OCU400 gene therapy: dosing began in Cohort 3 for retinitis pigmentosa; enrollment to complete by year-end; also to enroll LCA CEP290 patients.","Expanded pipeline: OCU500 mucosal COVID-19 vaccine licensed from Washington University; OCU410ST for Stargardt disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-028759","json":"https://secwatch.observer/filing/0001628280-22-028759.json","markdown":"https://secwatch.observer/filing/0001628280-22-028759.md","text":"https://secwatch.observer/filing/0001628280-22-028759.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828022028759/0001628280-22-028759-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828022028759/ocgn-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:12:02.965476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"88a7ce9a754a9e1c0ad35bf4c84ee5b98f8b545c","claim":"Ocugen, Inc. reported quarter ended September 30, 2022 results: net income $0.10 net loss per share, EPS $0.10 net loss per share.","evidence_excerpt":"Ocugen reported a $0.10 net loss per share for the three months ended September 30, 2022, compared to a $0.05 net loss per share for the three months ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000162828022028759/0001628280-22-028759-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Net income","value":"$0.10 net loss per share"},{"label":"EPS","value":"$0.10 net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}